These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 12829143)

  • 1. Is there a role for radiation therapy in the management of Hürthle cell carcinoma?
    Foote RL; Brown PD; Garces YI; McIver B; Kasperbauer JL
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1067-72. PubMed ID: 12829143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Favorable Outcome of Hurthle Cell Carcinoma of the Thyroid Treated With Total Thyroidectomy, Radioiodine, and Selective Use of External-Beam Radiotherapy.
    Zavitsanos P; Amdur RJ; Drew PA; Cusi K; Werning JW; Morris CG
    Am J Clin Oncol; 2017 Aug; 40(4):433-437. PubMed ID: 25730603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hürthle cell tumors: applying molecular markers to define a new management algorithm.
    Maxwell EL; Palme CE; Freeman J
    Arch Otolaryngol Head Neck Surg; 2006 Jan; 132(1):54-8. PubMed ID: 16415430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors in patients with Hürthle cell neoplasms of the thyroid.
    Lopez-Penabad L; Chiu AC; Hoff AO; Schultz P; Gaztambide S; Ordoñez NG; Sherman SI
    Cancer; 2003 Mar; 97(5):1186-94. PubMed ID: 12599224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hürthle cell carcinoma: a clinicopathological study of thirteen cases.
    Ozlem Küçük N; Kulak H; Tokmak E; Tar P; Ibiş E; Aras G
    Nucl Med Commun; 2006 Apr; 27(4):377-9. PubMed ID: 16531925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hurthle cell neoplasm: our experience].
    Cristofaro MG; Vescio G; Fava MG; Aversa C; Amantea M; Giudice M
    Ann Ital Chir; 2004; 75(6):663-8. PubMed ID: 15960361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hurthle cell tumor.
    Chen HY; Benjamin LB; Chen MF
    Int Surg; 1996; 81(2):168-70. PubMed ID: 8912085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological characteristics and long-term outcome in patients with distant metastases from differentiated thyroid cancer.
    Benbassat CA; Mechlis-Frish S; Hirsch D
    World J Surg; 2006 Jun; 30(6):1088-95. PubMed ID: 16736341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Adjuvant Radiation Therapy for Locoregionally Advanced Papillary Thyroid Carcinoma.
    Lee NK; Kim CY; Baek SK; Jung KY
    Oncology; 2016; 90(4):209-14. PubMed ID: 26986490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical treatment of Hurthle cell tumors of the thyroid.
    Chao TC; Lin JD; Chen MF
    World J Surg; 2005 Feb; 29(2):164-8. PubMed ID: 15650796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of follicular and Hürthle cell neoplasms of the thyroid gland.
    McHenry CR; Sandoval BA
    Surg Oncol Clin N Am; 1998 Oct; 7(4):893-910. PubMed ID: 9735140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aggressiveness of therapy and prognosis of patients with Hürthle cell papillary thyroid carcinoma.
    Besic N; Hocevar M; Zgajnar J; Petric R; Pilko G
    Thyroid; 2006 Jan; 16(1):67-72. PubMed ID: 16487016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unilateral lobectomy for Hurthle cell adenoma.
    Wasvary H; Czako P; Poulik J; Lucas R
    Am Surg; 1998 Aug; 64(8):729-32; discussion 732-3. PubMed ID: 9697901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Follicular carcinoma and Hürthle cell tumor of the thyroid].
    Miccoli P; Arganini M
    Chir Ital; 1994; 46(4):29-32. PubMed ID: 7882439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hürthle cell neoplasms of the thyroid gland: reassessment of functional capacity.
    Caplan RH; Abellera RM; Kisken WA
    Thyroid; 1994; 4(3):243-8. PubMed ID: 7833658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poorly differentiated thyroid carcinoma presenting with gross extrathyroidal extension: 1986-2009 Memorial Sloan-Kettering Cancer Center experience.
    Ibrahimpasic T; Ghossein R; Carlson DL; Chernichenko N; Nixon I; Palmer FL; Lee NY; Shaha AR; Patel SG; Tuttle RM; Balm AJ; Shah JP; Ganly I
    Thyroid; 2013 Aug; 23(8):997-1002. PubMed ID: 23311700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of radioactive iodine in the treatment of Hürthle cell carcinoma of the thyroid.
    Besic N; Vidergar-Kralj B; Frkovic-Grazio S; Movrin-Stanovnik T; Auersperg M
    Thyroid; 2003 Jun; 13(6):577-84. PubMed ID: 12930602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioactive Iodine Treatment Is Associated with Improved Survival for Patients with Hürthle Cell Carcinoma.
    Jillard CL; Youngwirth L; Scheri RP; Roman S; Sosa JA
    Thyroid; 2016 Jul; 26(7):959-64. PubMed ID: 27150319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival and prognosis in Hürthle cell carcinoma of the thyroid gland.
    Bhattacharyya N
    Arch Otolaryngol Head Neck Surg; 2003 Feb; 129(2):207-10. PubMed ID: 12578450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy in 29 patients with locally advanced follicular or Hürthle cell thyroid carcinoma: a phase 2 study.
    Besic N; Auersperg M; Gazic B; Dremelj M; Zagar I
    Thyroid; 2012 Feb; 22(2):131-7. PubMed ID: 22175241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.